Lipocine (STU:2VT0) COGS-to-Revenue : 0.00 (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Lipocine COGS-to-Revenue?

Lipocine's Cost of Goods Sold for the three months ended in Mar. 2024 was €0.00 Mil. Its Revenue for the three months ended in Mar. 2024 was €7.01 Mil.

Lipocine's COGS to Revenue for the three months ended in Mar. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Lipocine's Gross Margin % for the three months ended in Mar. 2024 was N/A%.

Lipocine COGS-to-Revenue Historical Data

The historical data trend for Lipocine's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipocine COGS-to-Revenue Chart

Lipocine Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

45.11

0.47

17.11

Lipocine Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Lipocine COGS-to-Revenue Calculation

Lipocine's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	9.331	/	-2.614
	=

Lipocine's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	7.008
	=	0.00

Lipocine (STU:2VT0) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Lipocine's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 7.008
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Lipocine COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Lipocine's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Lipocine (STU:2VT0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipocine Inc (STU:2VT0) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

LPCN:USA

Address

675 Arapeen Drive, Suite 202, Salt Lake City, UT, USA, 84108

Website

http://www.lipocine.com

Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107.

Lipocine (STU:2VT0) Headlines

No Headlines